Ultrasound-Guided Percutaneous Electrolysis Plus Exercise for Chronic Supraspinatus Tendinopathy
NCT07929675, Not applicable, Enrolling by invitation, DAVID CRUZ DÍAZ
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Ultrasound-Guided Percutaneous Electrolysis Plus Exercise for Chronic Supraspinatus Tendinopathy | ClinicalTrials.gov |
| NCT number | NCT07929675 | ClinicalTrials.gov |
| Status | Enrolling by invitation | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 58 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | DAVID CRUZ DÍAZ | ClinicalTrials.gov |
| Conditions | Supraspinatus Tendinopathy, Rotator Cuff Tendinopathy | ClinicalTrials.gov |
| Interventions | Ultrasound-Guided Percutaneous Electrolysis, Progressive Exercise-Based Rehabilitation | ClinicalTrials.gov |
| First posted | 2026-11-10 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change From Baseline in Shoulder Pain and Disability Index (SPADI) Total Score at 6 Weeks | Baseline and 6 weeks | Shoulder pain and disability will be assessed using the Shoulder Pain and Disability Index (SPADI), a validated 13-item self-reported questionnaire comprising pain (5 items) and disability (8 items) subscales. The total score ranges from 0 to 100, with higher scores indicating greater shoulder pain and disability. The primary outcome will be the change in the SPADI total score from baseline to week 6, calculated as the week 6 score minus the baseline score. Negative changes indicate improvement. | ClinicalTrials.gov |
| Secondary | Change From Baseline in Pain Intensity at Rest at 6 Weeks | Baseline and 6 weeks | Pain intensity at rest will be assessed using an 11-point Numerical Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Participants will report their average pain intensity at rest. Changes will be calculated as the week 6 score minus the baseline score, with negative values indicating pain reduction. | ClinicalTrials.gov |
| Secondary | Change From Baseline in Pain Intensity During Shoulder Movement at 6 Weeks | Baseline and 6 weeks | Pain intensity during shoulder movement will be assessed using an 11-point Numerical Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Participants will report their average pain intensity during shoulder movement. Changes will be calculated as the week 6 score minus the baseline score, with negative values indicating pain reduction. | ClinicalTrials.gov |
| Secondary | Change From Baseline in Night Pain Intensity at 6 Weeks | Baseline and 6 weeks | Night pain intensity will be assessed using an 11-point Numerical Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Participants will report their average shoulder pain intensity experienced at night. Changes will be calculated as the week 6 score minus the baseline score, with negative values indicating pain reduction. | ClinicalTrials.gov |
| Secondary | Change From Baseline in Pain Self-Efficacy Questionnaire (PSEQ) Total Score at 6 Weeks | Baseline and 6 weeks | Pain-related self-efficacy will be evaluated using the Pain Self-Efficacy Questionnaire (PSEQ), a validated 10-item self-report instrument assessing confidence in performing daily activities despite pain. Total scores range from 0 to 60, with higher scores indicating greater pain self-efficacy. Changes will be calculated as the week 6 score minus the baseline score, with positive values indicating improvement. | ClinicalTrials.gov |
| Secondary | Change From Baseline in Active Pain-Free Shoulder Range of Motion at 6 Weeks | Baseline and 6 weeks | Active pain-free shoulder range of motion (ROM) will be assessed using a universal goniometer in four movement planes: flexion, abduction, external rotation, and internal rotation. Each movement will be measured in degrees following standardized procedures. Two consecutive measurements will be performed for each movement, and their mean will be recorded for analysis. Changes will be calculated as the week 6 measurement minus the baseline measurement, with positive values indicating improved mobility. Each movement will be analyzed separately. | ClinicalTrials.gov |
| Secondary | Percentage of Participants Achieving a Clinically Important Improvement in SPADI at 6 Weeks | Baseline and 6 weeks | The proportion of participants achieving a clinically important improvement in shoulder pain and disability will be calculated using the change in the Shoulder Pain and Disability Index (SPADI) total score from baseline to week 6. A clinically important improvement will be defined using a prespecified threshold established in the study protocol. | ClinicalTrials.gov |
| Other | Exercise Program Adherence | Throughout the 6-week intervention period | Adherence to the prescribed exercise program will be assessed using participant training diaries and weekly supervision records. Adherence will be calculated as the percentage of completed exercise sessions relative to the total number of prescribed sessions during the six-week intervention period. | ClinicalTrials.gov |
| Other | Percutaneous Electrolysis Treatment Adherence | Throughout the 6-week intervention period | Adherence to percutaneous electrolysis will be assessed in the experimental group by recording attendance at the six scheduled treatment sessions. Adherence will be expressed as the percentage of completed electrolysis sessions relative to the six prescribed sessions. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 36793454 | BACKGROUND | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)